{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:22:16Z","timestamp":1778613736723,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejca.2022.09.032","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:58:39Z","timestamp":1665061119000},"page":"33-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients"],"prefix":"10.1016","volume":"177","author":[{"given":"Khrystany T.","family":"Isebia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-0820","authenticated-orcid":false,"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodine P.S.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-8403","authenticated-orcid":false,"given":"Stefan A.J.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0983-6296","authenticated-orcid":false,"given":"Jean C.A.","family":"Helmijr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-7984","authenticated-orcid":false,"given":"Jaco","family":"Kraan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine M.","family":"Beaufort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai N.","family":"Van","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2506-3852","authenticated-orcid":false,"given":"Esther","family":"Oomen - de Hoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anieta M.","family":"Sieuwerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred F.J.","family":"van IJcken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam C.G.N.","family":"van den Hout - van Vroonhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutger W.W.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Oole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-0250","authenticated-orcid":false,"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C.M.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi H.","family":"Helgason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-3366","authenticated-orcid":false,"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice P.H.M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-7923","authenticated-orcid":false,"given":"Job","family":"van Riet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-2928","authenticated-orcid":false,"given":"Martijn P.","family":"Lolkema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2022.09.032_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ejca.2022.09.032_bib2","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1078-0432.CCR-18-0320","article-title":"Expression of AR-V7 and ARv(567es) in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.032_bib3","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.032_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Del Re","year":"2017","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.ejca.2022.09.032_bib5","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2022.09.032_bib6","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.09.032_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jmoldx.2018.01.008","article-title":"An in-depth evaluation of the validity and logistics surrounding the testing of AR-V7 mRNA expression in circulating tumor cells","volume":"20","author":"Sieuwerts","year":"2018","journal-title":"J Mol Diagn"},{"issue":"3","key":"10.1016\/j.ejca.2022.09.032_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1878-0261.12037","article-title":"Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions","volume":"11","author":"van Dessel","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2022.09.032_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2021.04.025","article-title":"Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: a multicenter biomarker study","volume":"152","author":"Conteduca","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.032_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer","volume":"136","author":"van der Doelen","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.09.032_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2019.08.005","article-title":"Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer","volume":"121","author":"Belderbos","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.032_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.032_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ejca.2022.09.032_bib14","first-page":"1535","article-title":"Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance","volume":"3","author":"Baille","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.032_bib15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpba.2011.10.010","article-title":"Quantification of cabazitaxel in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry: a practical solution for non-specific binding","volume":"59","author":"de Bruijn","year":"2012","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.ejca.2022.09.032_bib16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.ejca.2022.09.032_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.032_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2021.09.029","article-title":"Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects","volume":"159","author":"Aldea","year":"2021","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ejca.2022.09.032_bib19","doi-asserted-by":"crossref","first-page":"54708","DOI":"10.18632\/oncotarget.18025","article-title":"Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients","volume":"8","author":"Le\u00f3n-Mateos","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejca.2022.09.032_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12916-022-02244-0","article-title":"Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel","volume":"20","author":"Gurioli","year":"2022","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ejca.2022.09.032_bib21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2018.02.013","article-title":"Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA)","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2022.09.032_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","article-title":"Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA","volume":"80","author":"Sumanasuriya","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2022.09.032_bib23","doi-asserted-by":"crossref","DOI":"10.21037\/pcm.2018.09.01","article-title":"AR-V7 and treatment selection in advanced prostate cancer: are we there yet?","volume":"1","author":"Bastos","year":"2018","journal-title":"Precis Cancer Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.032_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.09.032_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1373\/clinchem.2018.287102","article-title":"Circulating tumor cells in prostate cancer: from discovery to clinical utility","volume":"65","author":"Pantel","year":"2019","journal-title":"Clin Chem"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:50Z","timestamp":1760733470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922007729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":25,"alternative-id":["S0959804922007729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}